They fund and do a lot of work beyond the horrible choices for initial RCTs. This fall we should hopefully see actual pharmaceutical interventions and a plethor

They fund and do a lot of work beyond the horrible choices for initial RCTs. This fall we should hopefully see actual pharmaceutical interventions and a plethora of research they’ve been publishing. The more important parts of their programs are the omics and tissue biopsy programs. May they hopefully turn the ship…